Overview: rs8099917 Genotype TestIntroduction: The rs8099917 Genotype Test tests for rs8099917 genotype to assess hepatitis C treatment response, helping guide antiviral therapy for liver disease. Affecting 1 in 100 people with hepatitis C, the genotype poses diagnostic challenges due to variable response. Following 2023 American Association for the Study of Liver Diseases (AASLD) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hepatology.
Other Names: rs8099917 SNP Test, Hepatitis C Response Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: rs8099917 testing began in the 2000s with research by Tanaka, who linked it to treatment outcome. PCR/sequencing advancements by Illumina improved detection, surpassing earlier genotyping methods.
Purpose: Detects rs8099917 genotype to assess hepatitis C treatment response, guides antiviral therapy, and evaluates patients with liver disease, aiming to improve cure rates.
Test Parameters: rs8099917 genotype
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of hepatitis.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document liver disease or hepatitis history. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cirrhosis), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect genotype, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Favorable genotype suggests better treatment response, guiding therapy. Early intervention might improve outcomes, while untreated cases lead to progression. Unfavorable genotype may require alternative treatments.
Specialist Consultation: Consult a hepatologist for interpretation.
Additional Supporting Tests: Viral load, liver function tests, or biopsy to confirm diagnosis.
Test Limitations: Specific to rs8099917; correlation with clinical status needed. False negatives possible with technical errors.
References: AASLD Guidelines, 2023; Nature Genetics, Tanaka Y, 2022.
